phrykt

Bioxytran, Inc (BIXT): who owns it and who trades it

As of Nov 5, 2026, BIXT insiders reported 1 purchase worth $126K in the last 12 months. The largest buyer was Alan M Hoberman (Director), with $126K.

Latest filing Nov 5, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, BIXT insiders reported $126K of open-market purchases and $0 of sales.

Purchases, 12 months
$126K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 18, 2025
Filed Nov 18, 2025

Purchases and sales by month

$1$1DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 18, 2025Alan M HobermanDirectorPurchase210,000$0.60$126KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alan M HobermanDirector$126K–Nov 18, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BIXT short interest

Low short interest. Less than 0.1% of BIXT shares are sold short. Over the last 7 reports the number of shares short went down 78%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Sep 30, 2026, 3,141 BIXT shares were sold short, 0.0% of the shares outstanding. At the average daily volume of 193,851 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.00%May 15Sep 300.02%

Days to cover

1.0May 15Sep 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Sep 30, 20263,1410.00%–193,8511.0
Aug 14, 20261300.00%–183,7041.0
Jul 15, 202614,9990.01%-2%83,2201.0
Jun 30, 202615,2990.01%+7%61,1991.0
Jun 15, 202614,3090.01%-0%142,7291.0
May 29, 202614,3300.01%+1%57,9931.0
May 15, 202614,1980.01%+4633%81,6821.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Bioxytran company events

Bioxytran filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementThe Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title: Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets Item 9.01 Financial Statements and Exhibits. Filing
  2. Aug 11, 2026AnnouncementThe Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title: Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with… Filing
  3. Mar 20, 2026AnnouncementThe Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, under the title: Bioxytran, Inc. Completes $1.2 Million Private Placement Item 9.01 Financial Statements and Exhibits. Filing
  4. Mar 13, 2026Leadership– Compensatory Arrangements of Certain Officers The Board of Directors of Bioxytran, Inc. recently approved a performance-based equity award to David Platt, the Company’s Chief Executive Officer. Filing
  5. Mar 2, 2026AnnouncementThe Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title: Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 Item 9.01 Financial Statements and Exhibits. Filing
  6. Feb 17, 2026AgreementBioxytran entered into a commercial Distribution Agreement, attached hereto as Exhibit 10.90, with Khoury Medical LTD, a company focused on the development and commercialization of plant-derived dietary supplements. Filing
  7. Feb 11, 2026AnnouncementThe Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-M Item 9.01 Financial Statements and Exhibits. Filing
  8. Jan 5, 2026LeadershipMike Sheikh was terminated as an Officer of Bioxytran, Inc. Filing
  9. Dec 15, 2025LeadershipAnders Utter notified Bioxytran, Inc. that he was resigning from the Company’s Board of Directors and as Chair of the Audit Committee, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Bioxytran financials

Questions about Bioxytran, Inc (BIXT) stock

Are BIXT insiders buying or selling?

In the last 12 months, BIXT insiders reported 1 open-market purchase worth $126K and no sales. The latest trade was on Nov 18, 2025. See every trade.

What is the short interest in BIXT?

As of Sep 30, 2026, 3,141 BIXT shares were sold short, 0.0% of the shares outstanding. At the average daily volume of 193,851 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.